Optimized Antithrombotic Therapy of Acute Myocardial Infarction With Left Ventricular Mural Thrombus
Status:
Not yet recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
A multi-center study will be done to explore the optimal regimen of antithrombotic therapy
for acute myocardial infarction with left ventricular mural thrombus. The investigators will
evaluate the different combinations of antiplatelet drugs and anticoagulants for at least one
month, such as aspirin 100mg qd+clopidogrel 75mg qd+warfarin (INR1.8-2.2), aspirin 100mg
qd+clopidogrel 75mg qd+dabigatran 110mg bid, aspirin 100mg qd+ticagrelor 60mg bid+warfarin
(INR1.8-2.2), and aspirin 100mg qd+ticagrelor 60mg bid+dabigatran 110mg bid. Transthoracic
two-dimensional echocardiography will be done at the 1-month, 3-month and 6-month follow-ups
to evaluate the left ventricular mural thrombus and determinate whether the antithrombotic
therapy regimen could be regulated to double antiplatelet or anticoagulant+clopidogrel 75mg
qd/ticagrelor 60mg bid. Then the investigators will complete the 12-month follow-up to
evaluate the efficacy and safety of the optimal antithrombotic therapy regimen for acute
myocardial infarction with left ventricular mural thrombus.
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University